{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:48Z","timestamp":1786991868772,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872824"],"award-info":[{"award-number":["81872824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81690261"],"award-info":[{"award-number":["81690261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jconrel.2020.03.049","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T20:32:32Z","timestamp":1585945952000},"page":"10-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier"],"prefix":"10.1016","volume":"325","author":[{"given":"Shiqi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9598-9111","authenticated-orcid":false,"given":"Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-9911","authenticated-orcid":false,"given":"Tao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0721-7678","authenticated-orcid":false,"given":"Qin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-5394","authenticated-orcid":false,"given":"Zhirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2020.03.049_bb0005","series-title":"Cutaneous Malignant Melanoma, Mayo Clinic Proceedings","first-page":"500","author":"Cummins","year":"2006"},{"issue":"5","key":"10.1016\/j.jconrel.2020.03.049_bb0010","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/jid.2013.471","article-title":"Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin","volume":"134","author":"Tse","year":"2014","journal-title":"J. Investig. Dermatol."},{"issue":"10","key":"10.1016\/j.jconrel.2020.03.049_bb0015","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s12274-019-2488-3","article-title":"Novel fibronectin-targeted nanodisk drug delivery system displayed superior efficacy against prostate cancer compared with nanospheres","volume":"12","author":"Wang","year":"2019","journal-title":"Nano Res."},{"issue":"14","key":"10.1016\/j.jconrel.2020.03.049_bb0020","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.lfs.2004.09.021","article-title":"Cell cycle specific induction of apoptosis and necrosis by paclitaxel in the leukemic U937 cells","volume":"76","author":"Liao","year":"2005","journal-title":"Life Sci."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2020.03.049_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drup.2007.02.003","article-title":"Cancer drug resistance: the central role of the karyotype","volume":"10","author":"Duesberg","year":"2007","journal-title":"Drug Resist. Updat."},{"issue":"9","key":"10.1016\/j.jconrel.2020.03.049_bb0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jconrel.2020.03.049_bb0035","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.2004.12.128","article-title":"Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study","volume":"22","author":"Gradishar","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.jconrel.2020.03.049_bb0040","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2020.03.049_bb0045","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.biomaterials.2011.10.050","article-title":"Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types","volume":"33","author":"Bae","year":"2012","journal-title":"Biomaterials"},{"issue":"33","key":"10.1016\/j.jconrel.2020.03.049_bb0050","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1016\/j.biomaterials.2011.07.051","article-title":"PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy","volume":"32","author":"Jiang","year":"2011","journal-title":"Biomaterials"},{"issue":"22","key":"10.1016\/j.jconrel.2020.03.049_bb0055","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2020.03.049_bb0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1736","article-title":"Promoting apoptosis as a strategy for cancer drug discovery","volume":"5","author":"Fesik","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2020.03.049_bb0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/adma.201404498","article-title":"Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene","volume":"27","author":"Jiang","year":"2015","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2020.03.049_bb0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","article-title":"Apo2L\/TRAIL and its death and decoy receptors","volume":"10","author":"LeBlanc","year":"2003","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.jconrel.2020.03.049_bb0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.cdd.4401185","article-title":"Protein-based therapeutic approaches targeting death receptors","volume":"10","author":"French","year":"2003","journal-title":"Cell Death Differ."},{"issue":"6","key":"10.1016\/j.jconrel.2020.03.049_bb0080","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.neo.7900203","article-title":"TRAIL\/Apo-2L: mechanisms and clinical applications in cancer","volume":"3","author":"Srivastava","year":"2001","journal-title":"Neoplasia"},{"issue":"53","key":"10.1016\/j.jconrel.2020.03.049_bb0085","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","article-title":"TRAIL and apoptosis induction by TNF-family death receptors","volume":"22","author":"Wang","year":"2003","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jconrel.2020.03.049_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","article-title":"Apoptosis control by death and decoy receptors","volume":"11","author":"Ashkenazi","year":"1999","journal-title":"Curr. Opin. Cell Biol."},{"issue":"5","key":"10.1016\/j.jconrel.2020.03.049_bb0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0952-7915(98)80224-0","article-title":"TRAIL: a molecule with multiple receptors and control mechanisms","volume":"10","author":"Griffith","year":"1998","journal-title":"Curr. Opin. Immunol."},{"issue":"12","key":"10.1016\/j.jconrel.2020.03.049_bb0100","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s10495-011-0649-2","article-title":"Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy","volume":"16","author":"Ivanov","year":"2011","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.jconrel.2020.03.049_bb0105","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3892\/or.2015.3869","article-title":"Inhibition of the autophagy flux by gingerol enhances TRAIL-induced tumor cell death","volume":"33","author":"Nazim","year":"2015","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.jconrel.2020.03.049_bb0110","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/sj.cgt.7700597","article-title":"Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect","volume":"10","author":"Seol","year":"2003","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2020.03.049_bb0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drup.2004.03.002","article-title":"Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications","volume":"7","author":"Shankar","year":"2004","journal-title":"Drug Resist. Updat."},{"issue":"8","key":"10.1016\/j.jconrel.2020.03.049_bb0120","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2020.03.049_bb0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2020.03.049_bb0130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomedicine"},{"issue":"28","key":"10.1016\/j.jconrel.2020.03.049_bb0135","doi-asserted-by":"crossref","first-page":"13673","DOI":"10.1039\/C8NR03297A","article-title":"A novel \u03b1-enolase-targeted drug delivery system for high efficacy prostate cancer therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Nanoscale"},{"issue":"11","key":"10.1016\/j.jconrel.2020.03.049_bb0140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.addr.2009.06.001","article-title":"Recent advances in the use of cell-penetrating peptides for medical and biological applications","volume":"61","author":"Fonseca","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"26","key":"10.1016\/j.jconrel.2020.03.049_bb0145","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1016\/j.biomaterials.2013.04.065","article-title":"The relationship between the cyclic-RGDfK ligand and \u03b1v\u03b23 integrin receptor","volume":"34","author":"Mondal","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2020.03.049_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2013.10.003","article-title":"RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system","volume":"173","author":"Sakurai","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.03.049_bb0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2015.09.009","article-title":"A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin \u03b1v\u03b23 for the treatment of melanoma","volume":"217","author":"Shi","year":"2015","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2020.03.049_bb0160","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.biomaterials.2013.12.018","article-title":"Anti-tumor efficacy of c (RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin","volume":"35","author":"Song","year":"2014","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2020.03.049_bb0165","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/bip.20989","article-title":"Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery","volume":"90","author":"Torchilin","year":"2008","journal-title":"Pept. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2020.03.049_bb0170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:PHAM.0000019289.61978.f5","article-title":"Cell penetrating peptides in drug delivery","volume":"21","author":"Snyder","year":"2004","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2020.03.049_bb0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1359-6446(03)02623-0","article-title":"Peptide and protein drug delivery to and into tumors: challenges and solutions","volume":"8","author":"Torchilin","year":"2003","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.jconrel.2020.03.049_bb0180","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1021\/acsnano.8b03800","article-title":"Enhanced transdermal drug delivery by transfersome-embedded oligopeptide hydrogel for topical chemotherapy of melanoma","volume":"12","author":"Jiang","year":"2018","journal-title":"ACS Nano"},{"issue":"16","key":"10.1016\/j.jconrel.2020.03.049_bb0185","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1002\/adfm.201303222","article-title":"Gel\u2013liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy","volume":"24","author":"Jiang","year":"2014","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2020.03.049_bb0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biomaterials.2016.09.001","article-title":"Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment","volume":"108","author":"Song","year":"2016","journal-title":"Biomaterials"},{"issue":"23","key":"10.1016\/j.jconrel.2020.03.049_bb0195","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1016\/j.biomaterials.2014.04.037","article-title":"Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells","volume":"35","author":"Zhang","year":"2014","journal-title":"Biomaterials"},{"issue":"27","key":"10.1016\/j.jconrel.2020.03.049_bb0200","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1016\/j.biomaterials.2013.05.018","article-title":"Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer","volume":"34","author":"Kim","year":"2013","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2020.03.049_bb0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jconrel.2007.05.011","article-title":"Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome","volume":"120","author":"Yang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.03.049_bb0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jconrel.2018.03.019","article-title":"A brain targeting functionalized liposomes of the dopamine derivative &ITN&IT-3, 4-bis(pivaloyloxy)-dopamine for treatment of Parkinson\u2019s disease","volume":"277","author":"Qu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2020.03.049_bb0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jconrel.2014.07.009","article-title":"sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib","volume":"192","author":"Loi","year":"2014","journal-title":"J. Control. Release"},{"issue":"14","key":"10.1016\/j.jconrel.2020.03.049_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201805888","article-title":"Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade","volume":"31","author":"Zhou","year":"2019","journal-title":"Adv. Mater."},{"issue":"10","key":"10.1016\/j.jconrel.2020.03.049_bb0225","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1021\/mp400566a","article-title":"PEG-stabilized bilayer nanodisks as carriers for doxorubicin delivery","volume":"11","author":"Zhang","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.03.049_bb0230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2018.06.006","article-title":"Nanodisk-based glioma-targeted drug delivery enabled by a stable glycopeptide","volume":"284","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.jconrel.2020.03.049_bb0235","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/sj.gt.3302910","article-title":"Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery","volume":"14","author":"Khalil","year":"2007","journal-title":"Gene Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2020.03.049_bb0240","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.addr.2011.09.006","article-title":"pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates","volume":"64","author":"Felber","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2020.03.049_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2013.01.016","article-title":"Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection","volume":"167","author":"Sharma","year":"2013","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2020.03.049_bb0250","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/nn102722z","article-title":"Gold nanorod\u2212 photosensitizer complex for near-infrared fluorescence imaging and photodynamic\/photothermal therapy in vivo","volume":"5","author":"Jang","year":"2011","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.jconrel.2020.03.049_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2020.03.049_bb0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/nn402669w","article-title":"In vivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools","volume":"8","author":"Bigini","year":"2014","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.jconrel.2020.03.049_bb0265","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1021\/nn200986z","article-title":"Biodistribution of amino-functionalized diamond nanoparticles. in vivo studies based on 18F radionuclide emission","volume":"5","author":"Rojas","year":"2011","journal-title":"ACS Nano"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2020.03.049_bb0270","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2011.04.008","article-title":"PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy","volume":"412","author":"Yoshizawa","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.jconrel.2020.03.049_bb0275","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/mp3005808","article-title":"Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and paclitaxel based on hyaluronic acid-based multifunctional nanocarrier","volume":"10","author":"Yao","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2020.03.049_bb0280","article-title":"eR, pR, HeR2, Ki-67 and cK5 in early and late relapsing breast cancer\u2014reduced cK5 expression in metastases","volume":"7","author":"Joensuu","year":"2013","journal-title":"Breast Cancer"},{"issue":"28","key":"10.1016\/j.jconrel.2020.03.049_bb0285","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2020.03.049_bb0290","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1021\/tx800002r","article-title":"Cardiotoxicity of antitumor drugs","volume":"21","author":"Menna","year":"2008","journal-title":"Chem. Res. Toxicol."},{"issue":"2","key":"10.1016\/j.jconrel.2020.03.049_bb0295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jbt.20012","article-title":"Cardiotoxicity of doxorubicin\/paclitaxel combination in rats: effect of sequence and timing of administration","volume":"18","author":"Saad","year":"2004","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.jconrel.2020.03.049_bb0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.actbio.2015.05.021","article-title":"Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles","volume":"23","author":"Gao","year":"2015","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.jconrel.2020.03.049_bb0305","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/nn305860k","article-title":"Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo","volume":"7","author":"Al-Jamal","year":"2013","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.jconrel.2020.03.049_bb0310","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1021\/nn500216y","article-title":"Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment","volume":"8","author":"Xu","year":"2014","journal-title":"ACS Nano"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365920302017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:49:04Z","timestamp":1759160944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365920302017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":62,"alternative-id":["S0168365920302017"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.03.049","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2020.03.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}